Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date27 Sep 2020 |
100 Clinical Results associated with Hubei Ruihua Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Hubei Ruihua Pharmaceutical Co., Ltd.
100 Deals associated with Hubei Ruihua Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Hubei Ruihua Pharmaceutical Co., Ltd.